Seven controlled efficacy trials were conducted of<unk>  for treatment of major depressive disorder (MDD). Five of these trials showed no significant influence of<unk>  over placebo on depressive symptoms. In the remaining two trials, small but significant advantages of<unk>  over placebo were found. According to these two eight-week trials in adults,<unk>  has an antidepressant response after one week of treatment. After eight weeks it resulted in a 13% greater response than placebo. Remission rates, however, were not significantly different versus placebo. According to FDA staff in 2011, "it is unknown whether<unk>  has any advantages compared to other drugs in the antidepressant class." A 2019 review stated that "present studies do not suggest the superiority of<unk>  compared with other antidepressants." Development of<unk>  for generalized anxiety disorder (GAD) has been stopped as of 2017. While there is tentative evidence of a small benefit in GAD, there is a high rate of side effects.
Vilazodone
Hydrocodone
Nefazodone
Trazodone
Tapentadol
Naltrexone
Tramadol
Norhydrocodone